|Dr. Maurizio Chiriva Internati Ph.D.||Founder, Chairman, CEO & Pres||437.9k||N/A||1968|
|Mr. Gianluca Rotino||Chief Strategy & Innovation Officer and Director||4.81M||N/A||1972|
|Mr. Daniel Clark||Interim Chief Financial Officer||N/A||N/A||N/A|
|Mr. Ignacio Nunez||Chief Operating & Manufacturing Officer||N/A||N/A||1977|
|Dr. David M. Spencer||Chief Scientific Officer||N/A||N/A||1962|
|Dr. Scott Dahlbeck Pharm.D., M.D., PharmD||Chief Medical Officer||N/A||N/A||1962|
|Dr. Michael Ryan Ph.D.||Chief BioInformatics Research Computing Officer||N/A||N/A||N/A|
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Kiromic BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.